LLY

1,008.05

-0.05%↓

JNJ

229.41

-0.66%↓

ABBV

211.8

+0.02%↑

UNH

396.1

-0.48%↓

AZN

181.62

-2.05%↓

LLY

1,008.05

-0.05%↓

JNJ

229.41

-0.66%↓

ABBV

211.8

+0.02%↑

UNH

396.1

-0.48%↓

AZN

181.62

-2.05%↓

LLY

1,008.05

-0.05%↓

JNJ

229.41

-0.66%↓

ABBV

211.8

+0.02%↑

UNH

396.1

-0.48%↓

AZN

181.62

-2.05%↓

LLY

1,008.05

-0.05%↓

JNJ

229.41

-0.66%↓

ABBV

211.8

+0.02%↑

UNH

396.1

-0.48%↓

AZN

181.62

-2.05%↓

LLY

1,008.05

-0.05%↓

JNJ

229.41

-0.66%↓

ABBV

211.8

+0.02%↑

UNH

396.1

-0.48%↓

AZN

181.62

-2.05%↓

Начало・Списък с акции・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Затворен

СекторЗдравеопазване

3.06

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.93

Максимум

3.13

Ключови измерители
By Trading Economics
Приходи	4.1M -5.7M
Служители	34
EBITDA	3.1M -6.8M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+549.35% upside

Дивиденти
By Dow Jones
Следващи печалби	19.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-88M 300M
Предишно отваряне	3.06
Предишно затваряне	3.06

Настроения в новините

By Acuity

50%

171 / 346 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

8.275 / 9.312 Подкрепа & съпротива

Anavex Life Sciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.05.2026 г., 22:44 ч. UTC

Придобивния, сливания и поглъщания

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14.05.2026 г., 22:27 ч. UTC

Придобивния, сливания и поглъщания

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14.05.2026 г., 22:12 ч. UTC

Печалби

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14.05.2026 г., 21:52 ч. UTC

Придобивния, сливания и поглъщания

LVMH to Sell Marc Jacobs

15.05.2026 г., 00:00 ч. UTC

Печалби

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14.05.2026 г., 23:57 ч. UTC

Придобивния, сливания и поглъщания

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14.05.2026 г., 23:56 ч. UTC

Придобивния, сливания и поглъщания

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14.05.2026 г., 23:56 ч. UTC

Придобивния, сливания и поглъщания

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14.05.2026 г., 23:56 ч. UTC

Пазарно говорене

Gold Prices Rise on Strong Demand -- Market Talk

14.05.2026 г., 23:56 ч. UTC

Придобивния, сливания и поглъщания

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14.05.2026 г., 23:50 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

14.05.2026 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14.05.2026 г., 23:47 ч. UTC

Печалби

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14.05.2026 г., 23:47 ч. UTC

Печалби

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14.05.2026 г., 23:46 ч. UTC

Печалби

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14.05.2026 г., 23:46 ч. UTC

Печалби

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14.05.2026 г., 23:28 ч. UTC

Пазарно говорене

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14.05.2026 г., 23:00 ч. UTC

Пазарно говорене

Australia's One Nation Party Leads In The Polls -- Market Talk

14.05.2026 г., 22:46 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

14.05.2026 г., 22:46 ч. UTC

Пазарно говорене

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14.05.2026 г., 22:46 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

14.05.2026 г., 22:35 ч. UTC

Пазарно говорене

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14.05.2026 г., 22:11 ч. UTC

Придобивния, сливания и поглъщания

LVMH Agrees to Sell Marc Jacobs -- WSJ

14.05.2026 г., 22:06 ч. UTC

Пазарно говорене

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14.05.2026 г., 22:04 ч. UTC

Печалби

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14.05.2026 г., 22:04 ч. UTC

Печалби

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14.05.2026 г., 22:04 ч. UTC

Печалби

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14.05.2026 г., 22:00 ч. UTC

Печалби

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14.05.2026 г., 21:55 ч. UTC

Печалби

Nu Holdings 1Q EPS 18c >NU

14.05.2026 г., 21:55 ч. UTC

Печалби

Nu Holdings 1Q Rev $4.97B >NU

Сравнение с други в отрасъла

Ценова промяна

Anavex Life Sciences Corp Прогноза

Ценова цел

By TipRanks

549.35% нагоре

12-месечна прогноза

Среден 20 USD 549.35%

Висок 20 USD

Нисък 20 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Anavex Life Sciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на Anavex Life Sciences Corp през последните 3 месеца.

Техническа оценка

By Trading Central

8.275 / 9.312Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

171 / 346 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.